Ziwei Huang
General Hospital Of Chinese PLA Fuxing Road 28#
Haidian, 100853, China
Haidian, 100853, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 29 publications
Sex differences in primary Sjögren's disease: prognostic impact on mortality and cancer.
Journal: Biology of sex differences
Published: November 10, 2025
Comparative outcomes of first-line PD-1/PD-L1 inhibitors plus chemotherapy for advanced squamous non-small cell lung cancer: a systematic review and network meta-analysis of randomized clinical trials.
Journal: Translational lung cancer research
Published: January 22, 2025
Integrating genomic and pathological characteristics to enhance prognostic precision in advanced NSCLC.
Journal: NPJ precision oncology
Published: August 27, 2024
Chemokines and lymphocyte homing in Sjögren's syndrome.
Journal: Frontiers in immunology
Published: November 27, 2023
The transcription factor RhMYB17 regulates the homeotic transformation of floral organs in rose (Rosa hybrida) under cold stress.
Journal: Journal of experimental botany
Published: July 13, 2023
Anti-SSA/SSB-negative primary Sjögren's syndrome showing different clinical phenotypes: a retrospective study of 934 cases.
Journal: Advances in rheumatology (London, England)
Published: February 13, 2023
A bibliometric analysis of primary Sjögren's syndrome-associated lymphoma from 1991 to 2022.
Journal: Heliyon
Published: December 18, 2022
Evolutions in the management of non-small cell lung cancer: A bibliometric study from the 100 most impactful articles in the field.
Journal: Frontiers in oncology
Published: May 09, 2022
Research on primary Sjögren's syndrome in 2004-2021: a Web of Science-based cross-sectional bibliometric analysis.
Journal: Rheumatology international
Published: March 14, 2022
The gut microbiota modulates responses to anti-PD-1 and chemotherapy combination therapy and related adverse events in patients with advanced solid tumors.
Journal: Frontiers in oncology
Published: March 01, 2022
Immunotherapy plus chemotherapy showed superior clinical benefit to chemotherapy alone in advanced NSCLC patients after progression on osimertinib.
Journal: Thoracic cancer
Published: October 27, 2021
Last Updated: 09/26/2026